Core Stem Chemon Approval & Permits
- announced on April 30, 2025, that it has initiated procedures to maintain domestic permits for its stem cell therapy, Neuronata-R inj., following positive final results from its Phase...
- The application is considered a crucial step toward securing U.S.
- exhibited a positive biological mechanism, marked by an increase in key neuro-nutrients such as TGF-β, FSTL1, FGF2, BDNF, and VEGF, alongside a reduction in inflammatory indicators like NFL...
Corestem Chemon Pursues FDA Approval for ALS Stem Cell Therapy Following Positive Trial Results
Table of Contents
SEOUL, South Korea – Corestem Chemon Inc. announced on April 30, 2025, that it has initiated procedures to maintain domestic permits for its stem cell therapy, Neuronata-R inj., following positive final results from its Phase 3 clinical trial, Neuronata-Al, announced on April 24. The company submitted a license certificate to the South Korean Ministry of Food and Drug Safety (MFDS) on April 29.
Key Data and Clinical Improvements
The application is considered a crucial step toward securing U.S. Food and Drug Management (FDA) approval and maintaining its existing domestic license. Core data from a sub-analysis of slow-progressing ALS patients were included in the submission. According to Corestem Chemon, this patient group demonstrated significant improvements in key clinical indicators, including the ALS Functional Rating Scale-Revised (ALSFRS-R), the Survival Composite Index (CAFS), and lung function (SVC).
Furthermore, the company reported that Neuronata-R inj. exhibited a positive biological mechanism, marked by an increase in key neuro-nutrients such as TGF-β, FSTL1, FGF2, BDNF, and VEGF, alongside a reduction in inflammatory indicators like NFL and MCP-1. Corestem Chemon believes this data will provide a scientific basis for a precision medicine-based treatment strategy.
Self-reliant Verification and Regulatory Persuasion
Corestem Chemon emphasized that the data included in the license application underwent independent verification by a Global Contract Research Organization (CRO), and officials enhanced the final clinical results report (CSR). The company anticipates this will strengthen its position during deliberations with domestic and international regulators.
KFDA Review and Potential Outcomes
The MFDS is expected to review various scenarios, including formal permit approval, permit maintenance, or adjustments to target permits focusing on slow-progressing patients. Corestem Chemon anticipates a positive outcome through consultations based on scientific evidence.
Targeted Permit Model
The company stated that this application represents a targeted permit model for patient groups demonstrating therapeutic benefits, rather than a single-license strategy. Corestem Chemon expects this approach to expand drug prescriptions in the short term and reinforce its FDA accelerated strategy.
Impact on Sales and FDA Consultation
If the MFDS maintains the Neuronata-R inj. permit, Corestem Chemon projects increased drug prescriptions in medical institutions. Even if the permit is narrowed, the company expects the treatment to apply to more than half of slow-progressing patients, positively impacting sales volume.
Corestem Chemon is collaborating with a global CRO to finalize the data package for FDA submission and plans to initiate preliminary consultations with the FDA in the third quarter through a pre-Biologics License Application (BLA) or Type-C meeting.
Global Screening and ALS Treatment
The company anticipates Neuronata-Al will serve as a reliable reference in global screening, as the FDA recognizes a similar data pattern to the NFL biomarker strategy used during the approval process for the ALS drug Tofersen.
According to a Corestem Chemon official, the company is together consulting with domestic and foreign regulators, and the outcome of the South korean deliberation will significantly influence future FDA screening.
Global Demand and accessibility
Neuronata-R inj. has been prescribed to over 400 patients since its market introduction, including more than 120 foreign patients, confirming global demand for the treatment. The approval of the HTS-FRS formulation, which significantly extends the drug’s preservation period, is expected to improve long-distance transportation and prescription convenience, further expanding treatment accessibility.
A Corestem Chemon official stated that the precision target strategy is designed to overcome short-term limitations and meet the scientific requirements of global regulators in the long term.
Neuronata-R for ALS: Your Questions Answered
This article provides answers to common questions about Corestem Chemon’s ALS stem cell therapy, Neuronata-R inj., based solely on the facts in the provided text.
Q: what is Neuronata-R, and what is its purpose?
A: Neuronata-R inj. is a stem cell therapy developed by Corestem Chemon Inc.for the treatment of Amyotrophic Lateral Sclerosis (ALS). The therapy aims to address the debilitating effects of ALS and has been the subject of clinical trials.
Q: What is the current status of Neuronata-R?
A: As of April 30, 2025, Corestem Chemon has initiated procedures to maintain domestic permits for Neuronata-R inj. in South Korea. This follows positive final results from its Phase 3 clinical trial, Neuronata-Al, which were announced on april 24. A license certificate was submitted to the South Korean Ministry of Food and Drug Safety (MFDS) on April 29. The company is also pursuing FDA approval in the United States.
Q: What positive results were observed in the Neuronata-Al trial?
A: The trial showed significant improvements in key clinical indicators for slow-progressing ALS patients, including:
ALS Functional Rating Scale-Revised (ALSFRS-R)
Survival Composite Index (CAFS)
* Lung function (SVC)
The therapy also showed a positive biological mechanism, with an increase in neuro-nutrients like TGF-β, FSTL1, FGF2, BDNF, and VEGF, and a reduction in inflammatory indicators such as NFL and MCP-1.
Q: What is the meaning of Corestem Chemon’s application to the MFDS?
A: The application to the MFDS is crucial for maintaining the existing domestic license and is considered a critical step toward securing U.S. FDA approval.
Q: What are the potential outcomes of the MFDS review?
A: The MFDS is expected to consider several outcomes, including the approval of the permit, permit maintenance, or adjustments to target permits focusing on slow-progressing patients. corestem Chemon anticipates a positive outcome based on scientific evidence.
Q: What type of permit model is Corestem Chemon using?
A: The company is pursuing a targeted permit model, focusing on patient groups demonstrating therapeutic benefits, rather than a single-license strategy..
Q: How will Neuronata-R affect sales and prescriptions?
A: If the MFDS maintains the Neuronata-R inj. permit, Corestem Chemon projects increased drug prescriptions in medical institutions. Even if the permit is narrowed, the company expects the treatment to apply to more than half of slow-progressing patients, positively impacting sales volume.
Q: What are Corestem Chemon’s plans regarding FDA approval?
A: Corestem Chemon is collaborating with a global CRO to finalize the data package for FDA submission. They plan to initiate preliminary consultations with the FDA in the third quarter through a pre-Biologics License Application (BLA) or Type-C meeting.
Q: Has Neuronata-R been prescribed to patients outside of South Korea?
A: Yes, Neuronata-R inj. has been prescribed to over 400 patients since its market introduction, including more than 120 foreign patients, confirming the global demand for the treatment.
Q: How is the company addressing the long-term goals with this therapy?
A: According to a Corestem Chemon official, the precision target strategy is designed to overcome short-term limitations and meet the scientific requirements of global regulators in the long term.